TL-895
Based on 1 publication(s) in Google Scholar
TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor. TL-895 is active against recombinant BTK (average IC50: 1.5 nM) and inhibits only three additional kinases BLK, BMX (IC50 = 1.6 nM) and TXK with IC50 within tenfold of BTK activity. TL-895 inhibits BTK auto-phosphorylation at the Y223 phosphorylation site (IC50: 1-10 nM). The TL-895 effectively inhibits the production of inflammatory factors such as IL-8, IL-1β, MCP-1 and TNF-α by monocytes or macrophages, and reduces the chemotactic migration of MF cells towards SDF-1. TL-895 is used be for studies of chronic lymphocytic leukemia (CLL), myelofibrosis (MF), and B-cell malignancies.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.86%
- No. CAS: 1415823-49-2
- Fòrmula: C25H26FN5O2
- Peso molecular:447.50
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Covalent Screening Library
HY-L036
-
Differentiation Inducing Compound Library
HY-L038
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Anti-Blood Cancer Compound Library
HY-L079
-
Angiogenesis-Related Compound Library
HY-L088
-
Antidepressant Compound Library
HY-L108
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Chemokine Compound Library
HY-L132
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Mitochondrial Protection Compound Library
HY-L144
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cysteine Targeted Covalent Library
HY-L153
-
Autoimmune Disease Compound Library
HY-L156
-
Highly Selective Inhibitors Library
HY-L158
-
Cytokine Inhibitors Library
HY-L161
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Hematopathy Compound Library
HY-L171
-
Macrophage Related Compound Library
HY-L174
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) TL-895
MoreVer todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
|
IL-1β |
IL-8 |
IL-6 |
TL-895 in Ramos cells blocks BCR activation with an IC50 of 45.75 nM and also inhibits FcR activation in basophils with an IC50 of 1.01 μM[1].
TL-895 (0-10 μM, 17-24 h) inhibits the production of TNF-α by macrophages, but does not inhibit the production of IFN in PBMCs, and blocks the activation of macrophages activated by FcR stimulation[1].
TL-895 (0.1 nM-10 μM) effectively inhibits pBTK in B cells, Ramos cells, monocytes and Hel-92 cells[2].
TL-895 reduces the chemotaxis of Hel-92 cells and inhibits their migration towards SDF-1[2].
TL-895 reduces the expression of CD69 (an activation marker) on B cells in PBMCs and whole blood stimulated by B-cell receptor (BCR) (EC₅₀ values are 12 nM and 21 nM respectively)[2].
TL-895 inhibits the production of IL-8, IL-1β, MCP-1, MIP-1α and IL-6 in healthy monocytes[2].
TL-895 (0.01-50 μM, 1-4 days) effectively inhibits the proliferation of primary CLL cells, and at the effective concentration, it shows no significant toxicity to primary liver cells and HepG2 cells[3].
TL-895 (0.05-3 μM) does not inhibit antibody-dependent cellular cytotoxicity (ADCC) and is suitable for use in combination with therapeutic antibodies[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
TL-895 (25 mg/kg feed, average 3.35 mg/kg daily, p.o., for 4 months) alleviates arthritis by inhibiting FcR signaling, and it suppresses local inflammation rather than systemic immune regulation in the Pristane (HY-N7819)-induced DBA/1 lupus model in mice[1].
TL-895 (25 mg/kg, once daily, i.g., for 14-27 days) significantly inhibits tumor growth in the Mino model, but has limited effect in the Jeko-1, Maver-1, and Granta519 models in mice[3].
TL-895 (once daily, i.g., for 13-25 days) shows significant anti-tumor activity in the Diffuse large B-cell lymphoma (DLBCL) patient-derived xenograft (PDX) models mice model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BXSB-Yaa model established in C57BL/6mice[1]
-
Dosage:25 mg/kg feed, average 3.7 mg/kg daily
-
Administration:Oral administration (p.o.), for 11 weeks
-
Result:Significantly reduced the urine albumin/creatinine ratio (UACR). Significantly increased survival rate. Significantly reduced the scores of glomerular crescents, protein casts, interstitial inflammation and vasculitis.
Significantly reduced the levels of anti-dsDNA, anti-histone, and anti-Ro/SSA antibodies.
Reduced the expression of CD69 on B and T cells, and decreased the number of plasma cells (B220⁻).
-
Animal Model:Pristane-DBA/1 model established in C57BL/6mice[1]
-
Dosage:25 mg/kg feed, average 3.7 mg/kg daily
-
Administration:Oral administration (p.o.), for 4 months
-
Result:Significantly reduced the clinical arthritis score and the paw inflammation and injury score. Reduced some of the autoantibodies (anti-dsDNA, anti-histone, anti-Ro/SSA). Did not significantly affect the expression of IFN-regulating genes.
Partially reduced anti-dsDNA, anti-histone, and anti-Ro/SSA antibodies, but did not affect anti-Sm/RNP antibodies.
Increased the expression of CD69 on B cells, significantly reducing B220⁺ cells.
-
Animal Model:MCL xenograft model induced by Maver-1, Granta519, Mino, Jeko-1 established in 6-week-old female nude (NMRI:nu/nu) or CB17-SCID mice[3]
-
Dosage:25 mg/kg
-
Administration:Oral gavage (i.g.), once daily for 14 (Maver-1 and Granta519), 20 (Jeko-1) and 27 (Mino) days
-
Result:Showed significant anti-tumor activity in a specific MCL model.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 1415823-49-2
-
Appearance Solid
-
Peso molecular 447.50
-
Fòrmula C25H26FN5O2
-
Color White to off-white
-
SMILES
O=C(N1CCC(CNC2=NC=NC(N)=C2C3=CC=C(C=C3)OC4=CC=CC=C4)(CC1)F)C=C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res Commun
2025 Aug 22. PMID: 40844833
Solvente y solubilidad
DMSO : 250 mg/mL (558.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.65 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.65 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2346 mL | 11.1732 mL | 22.3464 mL | 55.8659 mL |
| 5 mM | 0.4469 mL | 2.2346 mL | 4.4693 mL | 11.1732 mL | |
| 10 mM | 0.2235 mL | 1.1173 mL | 2.2346 mL | 5.5866 mL | |
| 15 mM | 0.1490 mL | 0.7449 mL | 1.4898 mL | 3.7244 mL | |
| 20 mM | 0.1117 mL | 0.5587 mL | 1.1173 mL | 2.7933 mL | |
| 25 mM | 0.0894 mL | 0.4469 mL | 0.8939 mL | 2.2346 mL | |
| 30 mM | 0.0745 mL | 0.3724 mL | 0.7449 mL | 1.8622 mL | |
| 40 mM | 0.0559 mL | 0.2793 mL | 0.5587 mL | 1.3966 mL | |
| 50 mM | 0.0447 mL | 0.2235 mL | 0.4469 mL | 1.1173 mL | |
| 60 mM | 0.0372 mL | 0.1862 mL | 0.3724 mL | 0.9311 mL | |
| 80 mM | 0.0279 mL | 0.1397 mL | 0.2793 mL | 0.6983 mL | |
| 100 mM | 0.0223 mL | 0.1117 mL | 0.2235 mL | 0.5587 mL |
TL-895 Related Classifications
HY-139481 Related Classifications
Powered by Bioz